ACHV:NSD-Achieve Life Sciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.42

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

0.26M

Average Target Price

USD 25.50 (+123.29%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada. Address: 1040 West Georgia Street, Vancouver, BC, Canada, V6E 4H1

Company Website : http://www.achievelifesciences.com

Address : 1040 West Georgia Street, Vancouver, BC, Canada, V6E 4H1

Employees : 14

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.29

52 Week High : 18.26

Short Ratio : 0.84

52 Week Low : 4.51

Shorted Shares : 460,510

200 Day Moving Average : 9.49

Shorted Shares Previous Month : 440,816

50 Day Moving Average : 12.41

Shares Held By Insiders : 4.83%

Short Percentage : 8.00%

Shares Held by Institutions : 15.13%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

 USD61.26B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD55.25B 20.66 14.64
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD48.27B 14.76 12.06
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD33.58B 56.16 33.22
BGNE BeiGene, Ltd

N/A

 USD29.06B N/A N/A
RPRX Royalty Pharma plc

N/A

 USD28.27B 22.60 14.17
SGEN Seagen Inc

N/A

 USD27.38B 44.84 41.48
BNTX BioNTech SE

N/A

 USD26.25B -99,999.99 N/A
GMAB Genmab A/S

N/A

 USD22.15B 26.59 3.17
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ACHV

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 40.99% 78% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.99% 78% C+ 85% B
Trailing 12 Months  
Capital Gain 18.96% 43% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.96% 43% F 44% F
Trailing 5 Years  
Capital Gain -91.35% 12% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.35% 12% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -12.71% 22% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.71% 22% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 59.87% 46% F 22% F
Risk Adjusted Return -21.23% 26% F 22% F
Market Capitalization 0.07B 10% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.80 62% D- 87% B+
Price/Book Ratio 3.27 73% C 51% F
Price / Cash Flow Ratio -4.57 30% F 63% D
EV/EBITDA 0.36 55% F 93% A
Management Effectiveness  
Return on Equity -78.07% 40% F 15% F
Return on Invested Capital -97.65% 27% F 9% F
Return on Assets -42.31% 23% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.84 70% C- 68% D+
Short Percent 7.57% 39% F 26% F
Beta 1.29 58% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.